teva-english-logo-gray-web-5-1
Photo: Courtesy of Teva
23 December 2016Pharma

Teva sues nine companies for Copaxone patent infringement

Teva has filed a  complaint against nine pharmaceutical companies including Dr Reddy's Laboratories, Sandoz and Mylan for alleged patent infringement over Copaxone (glatiramer acetate injection), a treatment for patients with multiple sclerosis.  The case, which was filed on December 19 in the US District Court for the District of Delaware, arose after each of the nine companies filed an Abbreviated New Drug Application with the Food and Drug Administration.  The other companies which have been sued are Synthon Pharmaceuticals, Momenta Pharmaceuticals, Pfizer, Amneal Pharmaceuticals, Biocon and Apotex.  According to the complaint, the nine companies have allegedly sought approval to market a generic version of Copaxone before the expiration of US patent number 9,402,874, which is owned by Teva.  Teva has asked the court for a judgment that the nine companies have infringed its patent covering Copaxone.  It has also asked the court to enjoin them from bringing the generics to market, as well as for an award of damages.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
18 November 2026   A heated dispute over Boehringer’s diabetes drug empagliflozin has ended in a split decision, with the judge drawing a sharp line between what a patent discloses and what can be inferred from it.
Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
Pharma
12 November 2026   From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.